Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

217 results about "Adoptive cellular therapy" patented technology

Compositions and methods for chimeric antigen receptors specific to b cell receptors

The present invention relates to compositions and methods for treating or preventing a hematologic cancer or autoimmune disease of a mammal using anti-BCR CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a cancer or autoimmune disease associated with B cells comprising enriched stereotyped BCRs.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Antigen peptide and use thereof

An antigen peptide is provided specifically for treating individuals suffering from ovarian cancer, preferably based on BRCA1 gene c. 5470_5477del8 mutation. It is selected from amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 6, or derived by substitution, deletion and / or addition of at least one amino acid. The neoantigen polypeptides of the present disclosure can significantly activate T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro, stimulating the release of the cytokine IFN-y, indicating notable immunogenicity. This enhances T lymphocytes' ability to target and kill cancer cells from ovarian cancer patients carrying the BRCA1 gene c. 5470_5477del8 mutation. Additionally, the antigen peptide can activate and expand human T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro for adoptive cell therapy. The antigen peptide of the present disclosure addresses the gap in personalized antigen peptide therapies for ovarian cancer patients with BRCAl-c. 5470_5477del8 somatic mutations.
Owner:BEIJING EASENG MEDICAL SCI CO LTD

Receptors providing targeted costimulation for adoptive cell therapy

The present invention relates to a chimeric costimulatory antigen receptor (CoStAR) useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. The CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. The present invention also provides CoStAR proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof.
Owner:INSTIL BIO UK LTD +1

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.
Owner:JUNO THERAPEUTICS INC +1

BCMA specific VCAR compositions and methods for use

Disclosed are VHH chimeric antigen receptors (VCARs), VCAR transposons encoding VCARs of the disclosure, cells modified to express VCARs of the disclosure, as well as methods of making and methods of using the same for adoptive cell therapy.
Owner:POSEIDA THERAPEUTICS INC

Compositions and methods for enhancing adoptive T cell therapy

The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and / or recombinant nucleic acids encoding polypeptides having mutations capable of effecting altering T cell signaling, cytokine production, and / or in vivo persistence of therapeutic T cells comprising the mutations in tumors. The T cell signaling may be carried out by the NFAT, NF-[kappa] B, and / or AP-1 pathway. The disclosure also provides vectors and cells comprising the polypeptides and / or recombinant nucleic acid constructs and / or recombinant nucleic acids of the disclosure, as well as methods of making T cells for use in cell therapy, and methods of identifying mutations useful for improving T cell therapy.
Owner:RGT UNIV OF CALIFORNIA +1

Viral vectors and use thereof in adoptive cellular therapy

A vector containing a first nucleotide sequence S1 encoding a protein Z1, a second nucleotide sequence S2 encoding a protein Z2, a third nucleotide sequence S3 encoding a protein Y1, and a fourth nucleotide sequence S4 encoding a protein Y2, in which Z1 and Z2 form a first dimer and Y1 and Y2 form a second dimer, in which the first dimer Z1Z2 is different from the second dimer Y1Y2.
Owner:IMMATICS US INC

Methods and materials for assessing and treating cancers

PCT designated stage expiredWO2024238062A2Microbiological testing/measurementDisease diagnosisAdoptive cellular therapyTumor infiltrating lymphocyte therapy
This document relates to methods and materials involved in assessing a mammal (e.g., a human) having cancer (e.g., metastatic cancer), preparing a treatment for a mammal (e.g., a human) having cancer (e.g., metastatic cancer), and / or treating a mammal (e.g., a human) having cancer (e.g., metastatic cancer). For example, methods and materials for identifying a cancer (e.g., metastatic cancer) as being likely to respond to an adoptive cell therapy (e.g., a tumor infiltrating lymphocyte therapy) are provided.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

CD8 polypeptides, compositions, and methods of using thereof

The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.
Owner:IMMATICS US INC

A chimeric transmembrane receptor comprising at least one t-cell immunoreceptor with IG and ITIM domains (TIGIT) polypeptide region, t-cells expressing the chimeric human tigit switch receptor, vectors with nucleic acids encoding for the tigit receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy

The present invention inter alia relates to a chimeric transmembrane receptor comprising a polypeptide, wherein the polypeptide comprises at least one T cell immunoreceptor with Ig and ITIM domains (TIGIT) polypeptide region comprising a TIGIT extracellular ligand binding domain; further wherein the polypeptide comprises at least one non-TIGIT polypeptide region, wherein the at least one non-TIGIT polypeptide region comprises a transmembrane polypeptide region of CD2, CD40, HVEM, or CD30, and wherein the at least one non-TIGIT polypeptide region comprises at least one costimulatory cytoplasmic polypeptide domain, region or motif of CD2, CD40, HVEM, or CD30, or wherein the transmembrane domain is from TIGIT and further wherein the at least one non-TIGIT polypeptide region comprises at least one costimulatory cytoplasmic polypeptide domain, region or motif of CD2 or CD28. The invention also relates to corresponding nucleic acids, vectors and T-cells comprising or expressing the chimeric receptors, to a pharmaceutical composition comprising the T-cells, and to methods for preparing a T-cell for immunotherapy and for treating a disease, respectively, wherein the chimeric transmembrane receptor is used.
Owner:T-KNIFE GMBH

Receptors providing targeted co-stimulation for adoptive cell therapy

The present invention relates to chimeric co-stimulatory antigen receptors (CoStAR) useful in adoptive cell therapy (ACT) and cells comprising said CoStAR. CoStAR can be used as modulators that enhance the activity of cells that respond to determined antigens. The invention also provides CoStAR proteins, nucleic acids encoding said CoStAR, and therapeutic uses thereof.
Owner:INSTIL BIO INC

Methods for manufacturing adoptive cell therapies

The invention provides compositions and methods for manufacturing adoptive cell therapies. In particular embodiments, the invention provides methods of harvesting populations of cells, isolating and activating PBMCs, expanding T cells, and administering the T cell therapeutic to a subject in need thereof.
Owner:2SEVENTY BIO INC

Treating cancer

This document provides methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor T cells having reduced expression levels of a tumor necrosis factor receptor 2 (TNFR2) polypeptide in an adoptive cell therapy (e.g., a chimeric antigen receptor (CAR) T cell therapy) to treat a mammal (e.g., a human) having cancer are provided.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Methods and compositions for transducing lymphocytes and regulating the activity thereof

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and / or NK cells. The methods can include inhibitory RNA molecule(s) and / or engineered signaling polypeptides that can include a lymphoproliferative element, and / or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and / or genetically modified T cells and / or NK cells are provided, such as, for example, those including riboswitches, MRB-CARS, recognition domains, and / or pH-modulating agents.
Owner:EXUMA BIOTECH CORP

Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Protease 3 (PR3) chimeric autoantibody receptor t cells and related methods and uses

Provided herein are cell and protein therapeutics comprising a protease 3 (PR3) antibody binding domain, such as a wild-type PR3 protein or a mutant PR3 protein, and methods of use thereof. Also provided herein are chimeric autoantibody receptors (CAARs) comprising an extracellular PR3 antibody binding domain. The provided CAAR comprises a CAAR wherein the extracellular PR3 antibody binding domain is a wild-type or mutant PR3 protein or fragment thereof capable of being specifically bound by an anti-PR3 antineutrophil cytoplasmic antibody (ANCA). Also provided herein are polynucleotides encoding the provided CAAR, genetically engineered cells, such as T cells, containing the provided CAAR, as well as related methods and uses thereof in adoptive cell therapy.
Owner:JUNO THERAPEUTICS INC

Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen

Provided herein are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM). Also provided are genetically engineered cells containing such BCMA-binding receptors for uses in adoptive cell therapy.
Owner:JUNO THERAPEUTICS INC +1

Tumor antigen and chemotactic factor co-coding system and application thereof

The invention belongs to the technical field of tumor immunity, and particularly relates to a tumor antigen and chemotactic factor co-coding system and application thereof. The invention provides a tumor antigen and chemotactic factor co-coding system. The tumor antigen and chemotactic factor co-coding system comprises a nucleotide sequence for coding a tumor antigen and a nucleotide sequence for coding a chemotactic factor. The tumor antigen and chemotactic factor co-coding system can flexibly replace an antigen sequence and chemotactic factor combination, is adaptive to different tumor types and various immunotherapy requirements, can be expanded to various solid tumor treatment scenes through a customized antigen-chemotactic factor combination in the future, and has a wide application prospect. The broad-spectrum application in tumor treatment means including tumor neoantigen vaccines, adoptive cell therapy and the like is realized.
Owner:SICHUAN UNIV

Immune cells for adoptive cell therapy

Methods are provided for generating unlimited immune cells with increased lifespan and high proliferation rate by modifying them to express BCL6 and genes that promote cell survival. Further methods are provided for generating and using said unlimited immune cells to treat diseases such as cancer.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Application of Tapinarof in improvement of tumor treatment effect

The invention discloses an application of Tapinarof in improvement of a tumor treatment effect. According to the application, a compound Tapinarof is found through screening, experimental research finds that the Tapinarof has an anti-tumor effect, and the Tapinarof can enhance the anti-tumor function of T cells, so that the curative effects of an immune checkpoint inhibitor and adoptive T cell therapy are improved, and the Tapinarof and the immune checkpoint inhibitor / adoptive cell transfer therapeutic agent have a synergistic effect in combined treatment of tumors. The discovery supports the potential value of the Tapinarof as an adjuvant therapy drug in clinical application of cancer immunotherapy.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Engineered lymphocytes expressing interleukin-15 and interleukin-21 and uses thereof

The present invention relates to a lymphocyte comprising a recombinant nucleic acid encoding a fusion protein comprising interleukin-15 (IL-15) fused to interleukin-21 (IL-21), and optionally further comprising a recombinant antigen receptor and further optionally rendered independent of CD28 co-stimulation and resistant to exhaustion as caused by checkpoint protein expression and activation. The invention further encompasses the use of such lymphocytes, particularly in therapeutic applications such as adoptive cell therapy for cancer, autoimmune diseases, or infectious diseases. Also included within the scope of the invention are fusion proteins comprising IL-15 and IL-21 domains, nucleic acids encoding such fusion proteins, and cells—such as lymphocytes or other suitable host cells—comprising these nucleic acids.
Owner:GENICITY LTD

Viral vectors and their use in adoptive cell therapy

UndeterminedDE202020006214U1Adoptive cellular therapyNucleotide
A nucleic acid sequence comprising: (i) a nucleotide sequence S1 encoding a CD8α polypeptide, (ii) a nucleotide sequence S2 encoding a CD8β polypeptide, (iii) a nucleotide sequence S3 encoding a T-cell receptor (TCR) α polypeptide, and (iv) a nucleotide sequence S4 encoding a TCRβ polypeptide, wherein the nucleotide sequences are arranged in tandem in a 5'-to-3' orientation S2-S1-S4-S3, wherein the CD8α polypeptide comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 11, and the CD8β polypeptide comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 12.
Owner:IMMATICS US INC

Compositions and systems for combinatorial therapies containing fucosylated cells and immune checkpoint inhibitors and methods of production and use thereof

Compositions, systems, and kits are disclosed that comprise at least one immune checkpoint inhibitor and at least one immune cell type for adoptive cell therapy, wherein the at least one immune cell type has been fucosylated ex vivo (fuco-ACT). Also disclosed are methods of making and using the compositions, systems, and kits.
Owner:TARGAZYME INC

Methods of selecting t cell lines and their donors for adoptive cell therapy

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient carrying / suffering from or suspected of carrying / suffering from a pathogen or cancer. Also disclosed are methods of selecting a donor from which an allogeneic T cell line is obtained for therapeutic administration to a patient carrying / suffering from or suspected of carrying / suffering from a pathogen or cancer.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Monocyte or macrophage compositions with enhanced Anti- tumor activity and uses thereof

Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered monocytes or engineered monocyte-derived macrophages that overexpress ID3 for the treatment of cancer.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +2

Methods for treatment using adoptive cell therapy

Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.
Owner:JUNO THERAPEUTICS INC

Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC +1